資訊|論壇|病例

搜索

首頁 醫(yī)學(xué)論壇 專業(yè)文章 醫(yī)學(xué)進(jìn)展 簽約作者 病例中心 快問診所 愛醫(yī)培訓(xùn) 醫(yī)學(xué)考試 在線題庫 醫(yī)學(xué)會議

您所在的位置:首頁 > 醫(yī)藥資訊 > 華裔研究員巧妙構(gòu)建新融合蛋白,解決粘膜疫苗傳輸問題(3)

華裔研究員巧妙構(gòu)建新融合蛋白,解決粘膜疫苗傳輸問題(3)

2011-02-16 09:58 閱讀:1753 來源:生物通 作者:大*勒 責(zé)任編輯:大彌勒
[導(dǎo)讀] 來自美國馬里蘭大學(xué)的研究人員巧妙的構(gòu)建了一種新型的融合蛋白,解決了粘膜疫苗的關(guān)鍵傳輸問題,并提出了一種可以簡化粘膜疫苗的制備,分配及傳遞過程的新策略,這一研究成果公布在Nature Biotechnology雜志上。 文章的通訊作者是馬里蘭大學(xué)華裔學(xué)者朱小平副
 
  原文摘要:
 
  Efficient mucosal vaccination mediated by the neonatal Fc receptor
 
  Almost all infectious diseases are initiated at mucosal surfaces, yet intramuscular or subcutaneous vaccination usually provides only minimal protection at sites of infection owing to suboptimal activation of the mucosal immune system. The neonatal Fc receptor (FcRn) mediates the transport of IgG across polarized epithelial cells lining mucosal surfaces. We mimicked this process by fusing a model antigen, herpes simplex virus type-2 (HSV-2) glycoprotein gD, to an IgG Fc fragment. Intranasal immunization, together with the adjuvant CpG, completely protected wild-type, but not FcRn knockout, mice after intravaginal challenge with virulent HSV-2 186. This immunization strategy induced efficient mucosal and systemic antibody, B- and T-cell immune responses, with stable protection for at least 6 months after vaccination in most of the immunized animals. The FcRn-IgG transcellular transport pathway may provide a general delivery route for subunit vaccines against many mucosal pathogens.

分享到:
  版權(quán)聲明:

  本站所注明來源為"愛愛醫(yī)"的文章,版權(quán)歸作者與本站共同所有,非經(jīng)授權(quán)不得轉(zhuǎn)載。

  本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的,且明確注明來源和作者,不希望被轉(zhuǎn)載的媒體或個人可與我們

  聯(lián)系zlzs@120.net,我們將立即進(jìn)行刪除處理

意見反饋 關(guān)于我們 隱私保護(hù) 版權(quán)聲明 友情鏈接 聯(lián)系我們

Copyright 2002-2024 Iiyi.Com All Rights Reserved